These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34786655)

  • 1. SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness.
    Cavallari I; Maddaloni E; Nusca A; Tuccinardi D; Buzzetti R; Pozzilli P; Grigioni F
    Am J Cardiovasc Drugs; 2022 May; 22(3):263-270. PubMed ID: 34786655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
    Hammerman A; Azuri J; Aboalhasan E; Arbel R
    Am J Cardiovasc Drugs; 2022 May; 22(3):325-331. PubMed ID: 34671945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Yan BW; Spahillari A; Pandya A
    Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
    Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
    Briasoulis A; Kuno T; Ueyama H
    Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging drug targets in heart failure treatment.
    Ghionzoli N; Gentile F; Del Franco AM; Castiglione V; Aimo A; Giannoni A; Burchielli S; Cameli M; Emdin M; Vergaro G
    Heart Fail Rev; 2022 Jul; 27(4):1119-1136. PubMed ID: 34273070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
    Senni M; Paulus WJ; Gavazzi A; Fraser AG; Díez J; Solomon SD; Smiseth OA; Guazzi M; Lam CS; Maggioni AP; Tschöpe C; Metra M; Hummel SL; Edelmann F; Ambrosio G; Stewart Coats AJ; Filippatos GS; Gheorghiade M; Anker SD; Levy D; Pfeffer MA; Stough WG; Pieske BM
    Eur Heart J; 2014 Oct; 35(40):2797-815. PubMed ID: 25104786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.